TrialThe Journal of clinical endocrinology and metabolism2016

N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.

Tore Hedbäck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.